NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient ...(rol which may cause actual results perfo...)

Date:7/23/2008

rol, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements. Certain factors which may affect future operating results are detailed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-Q for the three months ended March 31, 2008. In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Important Additional Information

A special meeting of NxStage stockholders will be held on Thursday, July 31, 2008 to obtain stockholder approval for the second closing of a $43 million private placement in NxStage. In connection with the private placement and required stockholder approval, NxStage filed with the SEC a definitive proxy statement on July 8, 2008. This proxy statement was mailed to NxStage's stockholders on or about July 9, 2008. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT NXSTAGE AND THE PRIVATE PLACEMENT. Investors and security holders may obtain free copies of these documents and other documents filed with the SEC at the SEC's website at http://www.sec.gov, at NxStage's website at http://www.nxstage.com or by writing to NxStage Medical
'/>"/>

SOURCE NxStage Medical, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
2. NxStage Medical Provides Update on Medisystems Acquisition
3. NxStage(R) Medical to Report Third Quarter 2007 Financial Results on Friday, November 2nd
4. Arbios Announces SEPET(TM) Manufacturing Agreement With NxStage Medical
5. NxStage Medical to Present at the Piper Jaffray Healthcare Conference on November 27, 2007
6. NxStage Medical Announces Needle Supply Agreement with DaVita
7. NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations
8. NxStage Medical to Present at William Blair Growth Stock Conference
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering